This is all I copied and pasted but the article talks about another company as well. It just spoke about how big pharmas are ready to buy small cap pharmas. This source says BTX is one of them.
BioTime is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. The company earlier this month reported it has submitted a Clinical Investigation Protocol to European regulatory authorities for approval to initiate studies for its Renevia stem cell delivery platform.
Did you notice that you are now touting the fact that Judy lied to you as a "good thing"?
" it has submitted a Clinical Investigation Protocol to European regulatory authorities for approval to initiate studies"
which cannot be actually examined until the CE Mark is on "renevia" as one of several recipes for rooster comb soup being used in Europe.
I gave you links to all this reality some months ago, right after your Judy call.
There will be no BUYOUT, here is why:
Dr. West took Biotime over in 2007. It at the time only had one blood plasma product, besides that it was pretty much a shell of a company. Since 2007 Biotime has grown from 0.30 to a high of $10 last year. West has acquired some of the best IP over that last 6 years, as well as personnel. He got BTX onto the NYSC, set up seven subsidiaries during that time, built a family of innovative stem cell research products and is now embarking on a family of therapeutic products.
Over the next two years as revenues kick in Biotime will start to rapidly branch their subsidiaries into IPO's. There will be a family of companies Biotime will own. OrthoCyte will offer cartilage/bone regeneration, OncoCyte will offer cancer detection and tumor treatment, ReCyte will offer heart and other anti-aging and regenerative therapies.
So it's really completely off the mark to think there will be a Biotime buyout, on the contrary Biotime has been and will continue to be the one to 'buyout other companies with innovative IP. This is why they started BioTime Acquisition Corp., or BAC.
Best of luck!
Buyout? That's a laugh. Open heart surgery costs on average 50K. Biotimes heart regen therapy starts clinical trials in months. If successful, therapy will probably cost as much as open heart surgery. So at that point forget partnering with J&J, Pfizer or Merck. Biotime will instantly become a $80-100 stock and have enough money to do it alone.
Clone, as you work trading in/out on this puppy, as you have already admitted, you know that if there is a "buy out" it will be by Takeunder Al, at around his basis, which is around 0.
Thus, those who like this puppy can learn to trade into accumulation so that they aren;t damaged.
I like the stock but, time and again, good news produces dramatic declines.
It is very frustrating. I think reg med is a long term dream but will probably happen.
Whether this will be in my lifetime is unclear.